257 related articles for article (PubMed ID: 27621329)
1. Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.
Bhatt VR; Steensma DP
J Oncol Pract; 2016 Sep; 12(9):786-92. PubMed ID: 27621329
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
4. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.
Nazha A; Hu ZH; Wang T; Lindsley RC; Abdel-Azim H; Aljurf M; Bacher U; Bashey A; Cahn JY; Cerny J; Copelan E; DeFilipp Z; Diaz MA; Farhadfar N; Gadalla SM; Gale RP; George B; Gergis U; Grunwald MR; Hamilton B; Hashmi S; Hildebrandt GC; Inamoto Y; Kalaycio M; Kamble RT; Kharfan-Dabaja MA; Lazarus HM; Liesveld JL; Litzow MR; Majhail NS; Murthy HS; Nathan S; Nishihori T; Pawarode A; Rizzieri D; Sabloff M; Savani BN; Schachter L; Schouten HC; Seo S; Shah NN; Solh M; Valcárcel D; Vij R; Warlick E; Wirk B; Wood WA; Yared JA; Alyea E; Popat U; Sobecks RM; Scott BL; Nakamura R; Saber W
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2139-2146. PubMed ID: 32781289
[TBL] [Abstract][Full Text] [Related]
5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
6. Impact of Epigenomic Hypermethylation at TP53 on Allogeneic Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndromes.
Wang W; Auer P; Zhang T; Spellman S; Carlson KS; Nazha A; Bolon YT; Saber W
Transplant Cell Ther; 2021 Aug; 27(8):659.e1-659.e6. PubMed ID: 33992829
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
Lindsley RC; Saber W; Mar BG; Redd R; Wang T; Haagenson MD; Grauman PV; Hu ZH; Spellman SR; Lee SJ; Verneris MR; Hsu K; Fleischhauer K; Cutler C; Antin JH; Neuberg D; Ebert BL
N Engl J Med; 2017 Feb; 376(6):536-547. PubMed ID: 28177873
[TBL] [Abstract][Full Text] [Related]
8. Transplantation for myelodysplastic syndromes 2013.
Vaughn JE; Scott BL; Deeg HJ
Curr Opin Hematol; 2013 Nov; 20(6):494-500. PubMed ID: 24104409
[TBL] [Abstract][Full Text] [Related]
9. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic cell transplantation for myelodysplastic syndrome.
Deeg HJ
Am Soc Clin Oncol Educ Book; 2015; ():e375-80. PubMed ID: 25993199
[TBL] [Abstract][Full Text] [Related]
11. MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes.
Pourhassan H; DeFor T; Trottier B; Dolan M; Brunstein C; Bejanyan N; Ustun C; Warlick ED
Bone Marrow Transplant; 2017 Apr; 52(4):532-538. PubMed ID: 27941767
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.
de Witte T; Bowen D; Robin M; Malcovati L; Niederwieser D; Yakoub-Agha I; Mufti GJ; Fenaux P; Sanz G; Martino R; Alessandrino EP; Onida F; Symeonidis A; Passweg J; Kobbe G; Ganser A; Platzbecker U; Finke J; van Gelder M; van de Loosdrecht AA; Ljungman P; Stauder R; Volin L; Deeg HJ; Cutler C; Saber W; Champlin R; Giralt S; Anasetti C; Kröger N
Blood; 2017 Mar; 129(13):1753-1762. PubMed ID: 28096091
[TBL] [Abstract][Full Text] [Related]
13. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
Zhang Z; Li X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
[TBL] [Abstract][Full Text] [Related]
14. Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens.
Saber W; Horowitz MM
Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):478-484. PubMed ID: 27913519
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic hematopoietic cell transplantation for myelodysplastic syndromes: lingering uncertainties and emerging possibilities.
Mukherjee S; Boccaccio D; Sekeres MA; Copelan E
Biol Blood Marrow Transplant; 2015 Mar; 21(3):412-20. PubMed ID: 25079875
[TBL] [Abstract][Full Text] [Related]
16. Relapse after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes: Analysis of Late Relapse Using Comparative Karyotype and Chromosome Genome Array Testing.
Yeung CCS; Gerds AT; Fang M; Scott BL; Flowers MED; Gooley T; Deeg HJ
Biol Blood Marrow Transplant; 2015 Sep; 21(9):1565-1575. PubMed ID: 25953732
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic cell transplantation for patients with myelodysplastic syndromes (MDS): when, how and for whom?
Marcondes M; Deeg HJ
Best Pract Res Clin Haematol; 2008 Mar; 21(1):67-77. PubMed ID: 18342814
[TBL] [Abstract][Full Text] [Related]
18. Transplantation Referral Patterns for Patients with Newly Diagnosed Higher-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia at Academic and Community Sites in the Connect® Myeloid Disease Registry: Potential Barriers to Care.
Tomlinson B; de Lima M; Cogle CR; Thompson MA; Grinblatt DL; Pollyea DA; Komrokji RS; Roboz GJ; Savona MR; Sekeres MA; Abedi M; Garcia-Manero G; Kurtin SE; Maciejewski JP; Patel JL; Revicki DA; George TI; Flick ED; Kiselev P; Louis CU; DeGutis IS; Nifenecker M; Erba HP; Steensma DP; Scott BL
Transplant Cell Ther; 2023 Jul; 29(7):460.e1-460.e9. PubMed ID: 37086851
[TBL] [Abstract][Full Text] [Related]
19. Optimizing stem cell transplantation in myelodysplastic syndromes: unresolved questions.
Warlick ED
Curr Opin Oncol; 2010 Mar; 22(2):150-4. PubMed ID: 20010295
[TBL] [Abstract][Full Text] [Related]
20. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.
Deeg HJ; Scott BL; Fang M; Shulman HM; Gyurkocza B; Myerson D; Pagel JM; Platzbecker U; Ramakrishnan A; Radich JP; Sandmaier BM; Sorror M; Stirewalt DL; Wilson WA; Storb R; Appelbaum FR; Gooley T
Blood; 2012 Aug; 120(7):1398-408. PubMed ID: 22767498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
